NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT): How Genentech Exit Could Shift Valuation and Future Growth Strategy
If you are tracking Adaptive Biotechnologies (ADPT), the news that its strategic collaboration and license agreement with Genentech will be winding down might catch your attention. The deal, first signed in 2018 to jointly explore innovative cancer cell therapies, is set to terminate in early 2026. This will free Adaptive from previous exclusivity constraints in oncology. Notably, this change will unlock a $33.7 million boost in non-cash revenue later this year, adding detail to the...